Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234713 | 0.95 | MAPT (0.32) | NPSR1GAACACNA1BNAMPTMEN1 | |
| SCHEMBL7466948 | 0.93 | NPSR1 (0.36) | NPSR1GAACACNA1BMEN1KMT2A | |
| SCHEMBL7471039 | 0.86 | NPSR1 (0.37) | NPSR1GAAMEN1KMT2AGNRHR | |
| Trifluoroacetic Acid SCHEMBL8742751 | 0.83 | CACNA1B (0.38) | NPSR1GAACACNA1BMEN1KMT2A | |
| SCHEMBL7470255 | 0.83 | NPSR1 (0.35) | NPSR1GAANAMPTMEN1KMT2A | |
| SCHEMBL7468576 | 0.82 | NPSR1 (0.39) | NPSR1GAACACNA1BMEN1KMT2A | |
| SCHEMBL7474812 | 0.81 | NPSR1 (0.36) | NPSR1GAANAMPTMEN1KMT2A | |
| Bromide SCHEMBL8592941 | 0.81 | NPSR1 (0.39) | NPSR1GAACACNA1BMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL8589290 | 0.81 | CACNA1B (0.36) | NPSR1GAACACNA1B | |
| SCHEMBL7471625 | 0.80 | NPSR1 (0.41) | NPSR1GAANAMPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362067-B2 | 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8324214-B2 | 1,3-dihydro-2H-pyrrolo[3,2-bpyridin-2-one derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-12-04 | — | — | US | disclosed |
| EP-2265582-B1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | SANOFI SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| EP-2294068-B1 | 1,3-DIHYDRO-2H-PYRROLO[3,2-B]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110071160-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,2-b]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | US | disclosed |
| EP-2294068-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,2-B]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi-Aventis (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2265582-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009133314-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,2-B]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009115685-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | WO | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | AVPR1B, AVPR1A, AVPR2 | NPSR1 25/4885GAA 4643/4885CACNA1B 186/4885 |
| US-20110071160-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,2-b]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | ALK, PDXK, OPRK1 | NPSR1 99/4885GAA 2758/4885CACNA1B 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.